PR-018: An Open-Label, Safety Extension of Study PR-011
Status:
Completed
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
A study to evaluate long term safety and effect on ability to thrive of EUR-1008 (APT-1008)
3,000 lipase units (Zenpep® [pancrelipase] delayed release capsules) in infants with exocrine
pancreatic insufficiency (EPI) due to cystic fibrosis (CF).